Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection. Revised Protocol 06, incorporating Protocol Amendments 03, 05, 06, 07, 08 and 10 + Amendment Number 09 Site-Specific - Ireland (1.0, dated 27-Oct-11)

Next Previous
Trial Profile

A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection. Revised Protocol 06, incorporating Protocol Amendments 03, 05, 06, 07, 08 and 10 + Amendment Number 09 Site-Specific - Ireland (1.0, dated 27-Oct-11)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asunaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 01 Jun 2018 Results (n=1239) of pooled analysis (NCT01012895, NCT01030432, NCT01051414, NCT01497834 and NCT01581203) published in the Infectious Diseases and Therapy
  • 28 Apr 2013 Results reporting sustained virological response rates at 12 and 24 weeks post-treatment were presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
  • 27 Apr 2013 Primary endpoint 'Sustained-virological-response-rate' has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top